Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, engineered cell therapy that is in a Phase 1/2a clinical trialfor recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/24/2025 07:17 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.
• [07/18/2025 07:11 PDT] ABEO Expected to Trade Up After Bullish Patterns Develop
• [07/11/2025 07:39 PDT] ABEO, Expected to Trade Lower After Bearish Insider Trading
• [07/09/2025 07:35 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.